ZA200106454B - Imidazo[4,5-c]-pyridine-4-on-derivatives. - Google Patents
Imidazo[4,5-c]-pyridine-4-on-derivatives. Download PDFInfo
- Publication number
- ZA200106454B ZA200106454B ZA200106454A ZA200106454A ZA200106454B ZA 200106454 B ZA200106454 B ZA 200106454B ZA 200106454 A ZA200106454 A ZA 200106454A ZA 200106454 A ZA200106454 A ZA 200106454A ZA 200106454 B ZA200106454 B ZA 200106454B
- Authority
- ZA
- South Africa
- Prior art keywords
- formula
- compound
- compounds
- physiologically acceptable
- substance
- Prior art date
Links
- -1 pyrrolidin-l-yl Chemical group 0.000 claims description 56
- 150000001875 compounds Chemical class 0.000 claims description 40
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 20
- 125000004432 carbon atom Chemical group C* 0.000 claims description 17
- 108010074860 Factor Xa Proteins 0.000 claims description 14
- 235000010290 biphenyl Nutrition 0.000 claims description 14
- 239000004305 biphenyl Substances 0.000 claims description 14
- 125000001624 naphthyl group Chemical group 0.000 claims description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 10
- 208000007536 Thrombosis Diseases 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 9
- 229910052794 bromium Inorganic materials 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 229910052740 iodine Inorganic materials 0.000 claims description 6
- 125000006239 protecting group Chemical group 0.000 claims description 6
- 206010002383 Angina Pectoris Diseases 0.000 claims description 5
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 5
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 206010022562 Intermittent claudication Diseases 0.000 claims description 5
- 208000006011 Stroke Diseases 0.000 claims description 5
- 238000002399 angioplasty Methods 0.000 claims description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 5
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 208000021156 intermittent vascular claudication Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- 208000037803 restenosis Diseases 0.000 claims description 5
- 239000012453 solvate Substances 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 125000002183 isoquinolinyl group Chemical class C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 125000004185 ester group Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 claims description 2
- 230000003301 hydrolyzing effect Effects 0.000 claims description 2
- 150000004866 oxadiazoles Chemical class 0.000 claims description 2
- 238000003797 solvolysis reaction Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 8
- 239000007788 liquid Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 description 12
- 108090000190 Thrombin Proteins 0.000 description 9
- 229960004072 thrombin Drugs 0.000 description 9
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 108010054265 Factor VIIa Proteins 0.000 description 5
- 230000002785 anti-thrombosis Effects 0.000 description 5
- 108010048049 Factor IXa Proteins 0.000 description 4
- 230000002429 anti-coagulating effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229940012414 factor viia Drugs 0.000 description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 4
- 230000009424 thromboembolic effect Effects 0.000 description 4
- 206010053567 Coagulopathies Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010014173 Factor X Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006219 1-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000005808 2,4,6-trimethoxyphenyl group Chemical group [H][#6]-1=[#6](-[#8]C([H])([H])[H])-[#6](-*)=[#6](-[#8]C([H])([H])[H])-[#6]([H])=[#6]-1-[#8]C([H])([H])[H] 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000004362 3,4,5-trichlorophenyl group Chemical group [H]C1=C(Cl)C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical class OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 1
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- NDPNAZHCBKSFAP-UHFFFAOYSA-N benzyl N-[[(butylsulfonylamino)-[(ethylsulfonylamino)-(methanesulfonamido)-(propylsulfonylamino)methyl]sulfonylamino]methyl]sulfamate Chemical group C(C1=CC=CC=C1)OS(=O)(=O)NCN(S(=O)(=O)C(NS(=O)(=O)CCC)(NS(=O)(=O)CC)NS(=O)(=O)C)NS(=O)(=O)CCCC NDPNAZHCBKSFAP-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- HUXULLJDEXUMOP-UHFFFAOYSA-N carbamimidoyl fluoride Chemical compound NC(F)=N HUXULLJDEXUMOP-UHFFFAOYSA-N 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003607 serino group Chemical class [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19900471A DE19900471A1 (de) | 1999-01-08 | 1999-01-08 | Imidazo[4,5c]-pyridin-4-on-derivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200106454B true ZA200106454B (en) | 2002-11-06 |
Family
ID=7893790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200106454A ZA200106454B (en) | 1999-01-08 | 2001-08-06 | Imidazo[4,5-c]-pyridine-4-on-derivatives. |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1149099A2 (zh) |
| JP (1) | JP2002534429A (zh) |
| KR (1) | KR20010086085A (zh) |
| CN (1) | CN1333772A (zh) |
| AR (1) | AR022220A1 (zh) |
| AU (1) | AU3041700A (zh) |
| BR (1) | BR9916774A (zh) |
| CA (1) | CA2357771A1 (zh) |
| CZ (1) | CZ20012407A3 (zh) |
| DE (1) | DE19900471A1 (zh) |
| HU (1) | HUP0105054A3 (zh) |
| NO (1) | NO20013384L (zh) |
| PL (1) | PL349341A1 (zh) |
| SK (1) | SK9442001A3 (zh) |
| WO (1) | WO2000040583A2 (zh) |
| ZA (1) | ZA200106454B (zh) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE280171T1 (de) | 1998-12-23 | 2004-11-15 | Bristol Myers Squibb Pharma Co | Stickstoffhaltige heterobicyclen als faktor-xa- hemmer |
| JP2004501918A (ja) * | 2000-06-23 | 2004-01-22 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | Ｘａ因子阻害剤としての１−（ヘテロアリール−フェニル）−縮合ピラゾール誘導体 |
| EP1414449A4 (en) | 2001-05-22 | 2005-04-06 | Bristol Myers Squibb Co | FACTOR XA BICYCLIC INHIBITORS |
| GB0215293D0 (en) | 2002-07-03 | 2002-08-14 | Rega Foundation | Viral inhibitors |
| GB0225399D0 (en) * | 2002-10-31 | 2002-12-11 | Merck Sharp & Dohme | Therapeutic agents |
| PT1569912E (pt) | 2002-12-03 | 2015-09-15 | Pharmacyclics Llc | Derivados 2-(2-hidroxibifenil-3-il)-1h-benzoimidazole-5- carboxamidina como inibidores do fator viia |
| AU2004309390B2 (en) | 2003-12-22 | 2011-06-02 | Gilead Sciences, Inc. | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment |
| JP2008524335A (ja) | 2004-12-21 | 2008-07-10 | ギリアド サイエンシズ， インコーポレイテッド | イミダゾ［４，５−ｃ］ピリジン化合物および抗ウイルス処置法 |
| JP2009501187A (ja) * | 2005-07-15 | 2009-01-15 | エフ．ホフマン−ラ ロシュ アーゲー | 新規なヘテロアリール縮合環式アミン |
| EP1942898B2 (en) | 2005-09-14 | 2014-05-14 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors for treating diabetes |
| JP5122462B2 (ja) | 2005-09-16 | 2013-01-16 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
| WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| ES2339298T3 (es) | 2006-07-07 | 2010-05-18 | Gilead Sciences, Inc. | Compuesto de piridazina novedoso y uso del mismo. |
| TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| UA99466C2 (en) | 2007-07-06 | 2012-08-27 | Гилиад Сайенсиз, Инк. | Crystalline pyridazine compound |
| JP6689821B2 (ja) * | 2014-08-12 | 2020-04-28 | シンジェンタ パーティシペーションズ アーゲー | 硫黄含有置換基を有する殺有害生物的に活性な複素環式誘導体 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW219935B (zh) * | 1991-12-25 | 1994-02-01 | Mitsubishi Chemicals Co Ltd | |
| AU741766B2 (en) * | 1997-12-01 | 2001-12-06 | Merck & Co., Inc. | Thrombin inhibitors |
-
1999
- 1999-01-08 DE DE19900471A patent/DE19900471A1/de not_active Withdrawn
- 1999-12-21 JP JP2000592291A patent/JP2002534429A/ja active Pending
- 1999-12-21 CZ CZ20012407A patent/CZ20012407A3/cs unknown
- 1999-12-21 SK SK944-2001A patent/SK9442001A3/sk unknown
- 1999-12-21 PL PL99349341A patent/PL349341A1/xx unknown
- 1999-12-21 CN CN99815465A patent/CN1333772A/zh active Pending
- 1999-12-21 CA CA002357771A patent/CA2357771A1/en not_active Abandoned
- 1999-12-21 AU AU30417/00A patent/AU3041700A/en not_active Abandoned
- 1999-12-21 KR KR1020017007074A patent/KR20010086085A/ko not_active Application Discontinuation
- 1999-12-21 WO PCT/EP1999/010236 patent/WO2000040583A2/de not_active Application Discontinuation
- 1999-12-21 BR BR9916774-3A patent/BR9916774A/pt not_active Application Discontinuation
- 1999-12-21 HU HU0105054A patent/HUP0105054A3/hu unknown
- 1999-12-21 EP EP99964639A patent/EP1149099A2/de not_active Withdrawn
-
2000
- 2000-01-07 AR ARP000100062A patent/AR022220A1/es unknown
-
2001
- 2001-07-06 NO NO20013384A patent/NO20013384L/no not_active Application Discontinuation
- 2001-08-06 ZA ZA200106454A patent/ZA200106454B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU3041700A (en) | 2000-07-24 |
| JP2002534429A (ja) | 2002-10-15 |
| WO2000040583A3 (de) | 2000-09-21 |
| HUP0105054A3 (en) | 2002-12-28 |
| BR9916774A (pt) | 2001-10-30 |
| EP1149099A2 (de) | 2001-10-31 |
| NO20013384D0 (no) | 2001-07-06 |
| WO2000040583A2 (de) | 2000-07-13 |
| SK9442001A3 (en) | 2002-05-09 |
| CN1333772A (zh) | 2002-01-30 |
| KR20010086085A (ko) | 2001-09-07 |
| CA2357771A1 (en) | 2000-07-13 |
| NO20013384L (no) | 2001-07-06 |
| HUP0105054A2 (hu) | 2002-05-29 |
| AR022220A1 (es) | 2002-09-04 |
| PL349341A1 (en) | 2002-07-15 |
| DE19900471A1 (de) | 2000-07-13 |
| CZ20012407A3 (cs) | 2001-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200106454B (en) | Imidazo[4,5-c]-pyridine-4-on-derivatives. | |
| ZA200103498B (en) | Imidazo[4,5-C-]-pyridine-4-one derivative with factor Xa inhibiting effect. | |
| JP2011021027A (ja) | キナゾリンＲｈｏキナーゼ阻害剤およびその中間体の製造方法 | |
| AU2004287416B2 (en) | CCR-2 antagonist salt | |
| WO1999042439A1 (en) | Novel thiobenzamides | |
| EP0822934B1 (en) | Antithrombotic amidinotetrahydropyridylalanine derivatives | |
| WO2018188446A1 (zh) | 一类吴茱萸碱类化合物及其制备方法与应用 | |
| CA3190745A1 (en) | Substituted tricyclic compounds | |
| MXPA06014366A (es) | Tetrahidroisoquinolinas sustituidas utilizadas en forma de inhibidores de mpm, metodo para su produccion y su uso en forma de farmacos. | |
| WO1999042462A1 (en) | Sulfonamides with antithrombotic activity | |
| AU2916500A (en) | Pyrazole-3-on-derivative as factor xa inhibitors | |
| SK11992002A3 (sk) | Derivát aminosulfonylbifenylu, jeho použitie a farmaceutický prostriedok, ktorý ho obsahuje | |
| ZA200007039B (en) | Biphenyl derivatives. | |
| US5731321A (en) | Endothelin receptor antagonists | |
| ZA200102565B (en) | 2-oxo-2h-quinoline derivatives. | |
| JP4699985B2 (ja) | カルボキサミド誘導体及びその第Ｘａ因子の阻害剤としての使用 | |
| EP1140821A1 (en) | Lactams | |
| JPS63166885A (ja) | グリコールウリル誘導体及びその用途 | |
| US20060217550A1 (en) | Process for the production of n-arylmorpholinones | |
| WO2008155334A2 (en) | Improved process of amide formation | |
| CZ20004026A3 (cs) | Derivát bifenylu, způsob jeho přípravy, jeho použití a farmaceutický prostředek, který ho obsahuje | |
| MXPA01006942A (en) | Imidazo[4,5-c]-pyridine-4-on-derivatives | |
| ZA200200114B (en) | Method for preparing substituted (1,4)diazepino(6,7,1-hi)indol-4-ones. | |
| CZ2001680A3 (cs) | Derivát 2-oxo-2H-chinoIinu, způsob jeho přípravy, jeho použití a farmaceutický prostředek, který ho obsahuje |